Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

H. Kushlaf · SciRah

Researcher profile · Semantic Scholar

H. Kushlaf

Share profile

H. Kushlaf — researcher profile on SciRah

h-index: 9
Works: 39
Citations: 378

Most-cited papers

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
J. Diaz-Manera, P. Kishnani, H. Kushlaf, Shafeeq Ladha +25 more
2021Lancet Neurology133 citations Open access
Semantic Scholar
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks
P. Kishnani, J. Diaz-Manera, A. Toscano, P. Clemens +23 more
2023JAMA Neurology41 citations Open access
Semantic Scholar
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial.
R. Barohn, B. Gajewski, M. Pasnoor, Alexandra R. Brown +54 more
2020JAMA Neurology40 citations Open access
Semantic Scholar
Genotype–phenotype correlations in valosin-containing protein disease: a retrospective muticentre study
M. Schiava, C. Ikenaga, R. Villar-Quiles, M. Caballero-Ávila +57 more
2022Journal of Neurology Neurosurgery & Psychiatry38 citations Open access
Semantic Scholar
Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy
Manisha Korb, A. Peck, L. Alfano, K. Berger +50 more
2022Orphanet Journal of Rare Diseases31 citations Open access
Semantic Scholar
104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07)
B. Schoser, Priya S. Kishnani, D. Bratkovic, Barry J. Byrne +79 more
2024Journal of Neurology28 citations Open access
Semantic Scholar
Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial
Priya S. Kishnani, J. Diaz-Manera, S. Illarioshkin, A. T. van der Ploeg +21 more
2025Journal of Neurology10 citations Open access
Semantic Scholar
Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease
Priya S. Kishnani, Barry J. Byrne, K. Claeys, J. Diaz-Manera +73 more
2024Journal of Patient-Reported Outcomes10 citations Open access
Semantic Scholar
Current status of clinical outcome measures in inclusion body myositis: a systematised review.
B. Roy, Matteo Lucchini, J. Lilleker, Namita A. Goyal +20 more
2022Clinical and Experimental Rheumatology10 citations Open access
Semantic Scholar
Provisional practice recommendation for the management of myopathy in VCP‐associated multisystem proteinopathy
B. Roy, A. Peck, T. Evangelista, G. Pfeffer +16 more
2023Annals of Clinical and Translational Neurology9 citations Open access
Semantic Scholar
Efficacy and safety results of the avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients
P. Kishnani, S. Attarian, J. Borges, F. Bouhour +21 more
2021Molecular Genetics and Metabolism7 citations
Semantic Scholar
Global variations in diagnostic methods and epidemiological estimates in Pompe disease: findings from a scoping review
R. Giugliani, Faryn Solomon, H. Kushlaf, Eric Wright +3 more
2025Orphanet Journal of Rare Diseases6 citations Open access
Semantic Scholar
Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial
P. Kishnani, J. Diaz-Manera, H. Kushlaf, Shafeeq Ladha +20 more
2023Molecular Genetics and Metabolism5 citations
Semantic Scholar
Efficacy and Safety Results of the Avalglucosidase alfa Phase 3 COMET Trial in Late-Onset Pompe Disease Patients (4195)
H. Kushlaf, S. Attarian, J. Borges, F. Bouhour +23 more
2021Neurology2 citations
Semantic Scholar
Abnormal Spontaneous Electromyographic Activity
Long Davalos, H. Kushlaf
20202 citations
Semantic Scholar
Neurological and neuroscience education: mitigating neurophobia to mentor health care providers (P1.9-081)
S. Sandrone, Jimmy V. Berthaud, Miguel Chuquilin Arista, Jacquelyne S. Cios +9 more
2019Neurology2 citations
Semantic Scholar
Clinically important improvements in 6-min walk distance (6MWD) and forced vital capacity (FVC) in adults with late-onset Pompe disease (LOPD) switching from alglucosidase alfa (alg) to cipaglucosidase alfa plus miglustat (cipa + mig) in the PROPEL study
B. Schoser, H. Kushlaf, S. Wenninger, N. Hummel +8 more
2025Molecular Genetics and Metabolism1 citations
Semantic Scholar
Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL
T. Mozaffar, D. Bratkovic, B. Byrne, K. Claeys +11 more
2024Molecular Genetics and Metabolism1 citations Open access
Semantic Scholar
P156 Muscle biopsy findings in a large cohort of patients affected by valosin containing protein disease: preliminary analysis of the international multicentric VCP study
M. Schiava, I. Nishino, M. Inoue, Y. Nishimori +44 more
2023Neuromuscular Disorders1 citations
Semantic Scholar
The avalglucosidase alfa phase 3 COMET trial in late-onset Pompe disease patients: Efficacy and safety results after 97 weeks
P. Kishnani, J. Diaz-Manera, H. Kushlaf, Shafeeq Ladha +21 more
2022Molecular Genetics and Metabolism1 citations Open access
Semantic Scholar
Comparing Four Medicines to Treat Pain from Cryptogenic Sensory Polyneuropathy—The PAIN-CONTRoLS Study
R. Barohn, Byron J. Gajewski, M. Pasnoor, L. Brown +56 more
20201 citations Open access
Semantic Scholar
Upper Extremity Peripheral Nerve Ultrasound Shows Proximal to Distal Tapering of Nerves in Demyelinating Charcot-Marie-Tooth Disease but Not in Acquired Inflammatory Demyelinating Neuropathies (PD1.004)
H. Kushlaf, V. Juel, L. Hobson-Webb
2013Neurology1 citations
Semantic Scholar
Multiple Sclerosis in a Patient with Friedreich's Ataxia (P4-6.016).
Yang Yu, H. Kushlaf
2024Neurology0 citations
Semantic Scholar
Lack of Relationship Between Myasthenia Gravis and COVID-19 Severity (P4-11.010)
Rasha Moussallem, Husam Sultani, C. Haddad, Rocio Garcia Santibanez +7 more
2024Neurology0 citations
Semantic Scholar
Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease
Antonio Toscano, B. Byrne, K. Claeys, J. Diaz-Manera +10 more
2024Molecular Genetics and Metabolism0 citations
Semantic Scholar
Effect Size Analysis of Cipaglucosidase Alfa Plus Miglustat Versus Alglucosidase Alfa in ERT-experienced Adults with Late-onset Pompe Disease in PROPEL (S21.003).
H. Kushlaf, D. Bratkovic, B. Byrne, K. Claeys +11 more
2024Neurology0 citations
Semantic Scholar
P028: Switching treatment to cipaglucosidase alfa+miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease
P. Kishnani, B. Byrne, K. Claeys, Paula R. Clemens +10 more
2024Genetics in Medicine Open0 citations Open access
Semantic Scholar
20947. ANÁLISIS DEL TAMAÑO DEL EFECTO DE CIPAGLUCOSIDASA ALFA MÁS MIGLUSTAT FRENTE A ALGLUCOSIDASA-ALFA EN ADULTOS CON ENFERMEDAD DE POMPE DE INICIO TARDÍO PRETRATADOS CON TERAPIA DE SUSTITUCIÓN ENZIMÁTICA
A. Aguinaga-Barrilero, J. A. Pérez, D. Bratkovic, B. Byrne +13 more
2024Neurology Perspectives0 citations Open access
Semantic Scholar
P371 Switching treatment to cipaglucosidase alfa+miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease
K. Claeys, B. Byrne, J. Diaz-Manera, M. Dimachkie +11 more
2023Neuromuscular Disorders0 citations
Semantic Scholar
P373 Effect size analysis of cipaglucosidase alfa + miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL
J. Diaz-Manera, D. Bratkovic, B. Byrne, K. Claeys +13 more
2023Neuromuscular Disorders0 citations
Semantic Scholar
2285 Efficacy and safety of avalglucosidase alfa in participants with late-onset pompe disease after 97 weeks of treatment during the COMET trial
Robert Henderson, Priya S. Kishnani, J. Diaz-Manera, H. Kushlaf +24 more
2022Abstracts0 citations Open access
Semantic Scholar
Patient Preference in Virtual Versus In-Person Visits in Neuromuscular Clinical Practice, a Multicenter Survey (1698)
Fnu Komal, Husam Al Sultani, Ali A. Habib, Z. Siddiqi +13 more
2021Neurology0 citations
Semantic Scholar
P.025 Efficacy and safety results of the avalglucosidase alfa phase 3 COMET trial in participants with late-onset Pompe disease (LOPD)
M. Tarnopolsky, S. Attarian, J. Borges, F. Bouhour +23 more
2021Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques0 citations Open access
Semantic Scholar
A Novel Myelin Protein Zero variant in Charcot-Marie-Tooth Disease Type 2I (P3.4-038)
H. Kushlaf
2019Neurology0 citations
Semantic Scholar
Motor neuronopathy and myelopathy in Leber’s hereditary optic neuropathy (P6.140)
R. Sawyer, A. Turner, H. Kushlaf
2017Neurology0 citations
Semantic Scholar
Needle electromyography practice pattern in patients taking novel oral anticoagulants: A survey-based study (P1.347)
Ikjae Lee, H. Kushlaf
2016Neurology0 citations
Semantic Scholar
Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) and Multiple Sclerosis (MS) in the Same Patient: Coincidence or Link? (P2.189)
N. Baba-Ahmed, A. Zabeti, H. Kushlaf
2016Neurology0 citations
Semantic Scholar
Cystinosis associated vasculopathy masquerading as atypical migraine headache (P1.032)
Daniel Terence Smith, H. Kushlaf
2015Neurology0 citations
Semantic Scholar
Provisional practice recommendation for the management of Provisional practice recommendation for the management of myopathy in VCP-associated multisystem proteinopathy myopathy in VCP-associated multisystem proteinopathy
Bhaskar Roy, A. Peck, T. Evangelista, G. Pfeffer +17 more
0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Diaz-Manera×20
Invite
J. Diaz-Manera — researcher profile on SciRah
B. Schoser×19
Invite
B. Schoser — researcher profile on SciRah
T. Mozaffar×17
Invite
T. Mozaffar — researcher profile on SciRah
M. Dimachkie×15
Invite
M. Dimachkie — researcher profile on SciRah

×10

Invite

Shafeeq Ladha — researcher profile on SciRah

Invite

V. Straub — researcher profile on SciRah

A. Kostera-Pruszczyk×10

Invite

A. Kostera-Pruszczyk — researcher profile on SciRah

F. Holdbrook×10

Invite

F. Holdbrook — researcher profile on SciRah

A. T. van der Ploeg×9

Invite

A. T. van der Ploeg — researcher profile on SciRah

S. Illarioshkin×9

Invite

S. Illarioshkin — researcher profile on SciRah

Invite

M. Roberts — researcher profile on SciRah

Invite

K. Haack — researcher profile on SciRah